Enhance Predictive In Vivo & In Vitro Oncology Models & Optimise Model Selection Balancing Translatability, Cost & Reproducibility to Better Predict Therapeutic Response
Welcome to the 13th Tumour Models London Summit!
With 5% of cancer drugs going into the clinic, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery, particularly with such a high price tag for clinical failure.
The 13th Tumour Models London Summit stands as the only industry-led meeting uniting pharma, biotech, and preclinical CROs from Europe to network and discuss new trends and innovations in tumour models. Attracting leading preclinical and translational expertise, this forum provides an essential platform for scientists and decision makers to hear about the latest innovations in in vivo and in vitro tumour modelling to de-risk their studies and accelerate their product’s journey from lab to patient.
Featuring in-depth industry discussions and actionable case studies, this event offers a unique exploration of the most pressing topics. Join the summit to:
Optimise Genomic Vendor Selection with AstraZeneca: Validate emerging genomic vendors by assessing the efficacy of various techniques to establish the most effective workflows and identify top service providers
Advance Precision Oncology with Econic Biosciences: Identify biomarkers of resistance and response in precision oncology using mono- and co-culture patient-derived organoids and xenopgraphs
Explore Human PDC Cell-Based Cancer Vaccines with PDC*line Pharma: Delve into the therapeutic potential of human PDC cell-based cancer vaccines by examining tumour resistance, evolution, and the tumour microenvironment in humanised mouse models
Unlock Novel Disease Insights with Digital Pathology & AI with Adaptimmune Therapeutics: Harness the power of digital pathology combined with AI analytics to gain groundbreaking insights into disease pathophysiology
Confidently Validate Drug Targets with 3D Models with AstraZeneca: Investigate the potential of 3D models to accurately validate drug targets and perform comprehensive preclinical safety assessments
Optimize Genomic Vendor Selection with AstraZeneca: Validate emerging genomic vendors by assessing the efficacy of various techniques to establish the most effective workflows and identify top service providers
Advance Precision Oncology with Econic Biosciences: Identify biomarkers of resistance and response in precision oncology using patient-derived organoids, comparing monoculture and co-culture models
Explore Human PDC Cell-Based Cancer Vaccines with PDC*line Pharma: Delve into the therapeutic potential of human PDC cell-based cancer vaccines by examining tumour resistance, evolution, and the tumour microenvironment in humanised mouse models
Unlock Novel Disease Insights with Digital Pathology & AI: Harness the power of digital pathology combined with AI analytics to gain groundbreaking insights into disease pathophysiology, presented by Adaptimmune Therapeutics
Confidently Validate Drug Targets with 3D Models with AstraZeneca: Investigate the potential of 3D models to accurately validate drug targets and perform comprehensive preclinical safety assessments
Expert Speakers Include
Expert Speakers Include
2024 Partners
" This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world "
Other Events in the Series
